Sanuwave Health (NASDAQ:SNWV – Get Free Report) and Enovis (NYSE:ENOV – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Institutional & Insider Ownership
42.5% of Sanuwave Health shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 14.4% of Sanuwave Health shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Sanuwave Health and Enovis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanuwave Health | 32.38% | 1,728.10% | 39.04% |
| Enovis | -47.96% | 12.03% | 4.91% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanuwave Health | 1 | 1 | 1 | 0 | 2.00 |
| Enovis | 1 | 1 | 10 | 0 | 2.75 |
Sanuwave Health presently has a consensus target price of $47.00, suggesting a potential upside of 1,063.37%. Enovis has a consensus target price of $40.38, suggesting a potential upside of 111.70%. Given Sanuwave Health’s higher probable upside, analysts plainly believe Sanuwave Health is more favorable than Enovis.
Volatility & Risk
Sanuwave Health has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Valuation & Earnings
This table compares Sanuwave Health and Enovis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanuwave Health | $44.05 million | 0.79 | $11.81 million | $0.24 | 16.83 |
| Enovis | $2.25 billion | 0.49 | -$1.18 billion | ($19.26) | -0.99 |
Sanuwave Health has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.
Summary
Sanuwave Health beats Enovis on 10 of the 14 factors compared between the two stocks.
About Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for Sanuwave Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanuwave Health and related companies with MarketBeat.com's FREE daily email newsletter.
